ADMA Biologics
ADMA
365 hedge funds and large institutions have $3.28B invested in ADMA Biologics in 2025 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 98 increasing their positions, 160 reducing their positions, and 64 closing their positions.
110% more call options, than puts
Call options by funds: $69.2M | Put options by funds: $32.9M
3.52% more ownership
Funds ownership: 88.39% → 91.91% (+3.5%)
2% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 64
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1% less funds holding
Funds holding: 368 → 365 (-3)
15% less capital invested
Capital invested by funds: $3.84B → $3.28B (-$562M)
39% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 160
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHCM
Sachem Head Capital Management
New York
|
+$154M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$87.5M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$55.8M |
| 4 |
CP
Caligan Partners
New York
|
+$45.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$36.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$45.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.5M |
| 3 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$32.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$32.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$30.4M |
ADMA Hedge Fund Activity: Q3 2025 in Review
365 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2025, worth a combined $3.28B — down 15% from $3.84B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new ADMA positions and 64 closed out — a net gain of 1 holder — while 98 added to existing stakes and 160 trimmed.
The largest buyer was Sachem Head Capital Management, opening a new position worth an estimated $154M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $45.1M sold.
- 365 institutional investors held ADMA Biologics (ADMA) as of Q3 2025, down from 368 in Q2 2025.
- Funds reported $3.28B of ADMA Biologics stock for Q3 2025, down 15% quarter-over-quarter.
- 65 funds opened new ADMA Biologics positions in Q3 2025 and 64 closed out, a net change of +1 holder.
- The largest ADMA Biologics buyer in Q3 2025 was Sachem Head Capital Management, an estimated $154M added.
- The largest ADMA Biologics seller in Q3 2025 was Driehaus Capital Management, an estimated $45.1M sold.
Based on aggregated 13F filings for Q3 2025.